Analysts See 120% Upside in Strata Critical Medical as Cathie Wood Exits Position

Strata Critical Medical is trading at $4.12 per share, a price that analysts say fails to reflect its growth potential — even as Cathie Wood’s ARK Invest exits its position. On April 13, 2026, ARK sold 182,767 shares of the company through two of its ETFs, worth approximately $738,378. That sale followed another sale of over 75,000 shares on April 10, part of a multi-day pattern signaling a deliberate reduction in exposure.

The selloff comes despite a growing chorus of Wall Street optimism. On the same day as ARK’s latest sale, two analysts initiated coverage with Buy ratings and $8 price targets. B. Riley’s Yuan Zhi cited Strata’s dominant position in U.S. organ transplant logistics, calling it the only end-to-end platform in the space. Craig-Hallum’s Bill Bonello noted major operational improvements over the past year that have yet to be priced into the stock.

TipRanks data shows a Strong Buy consensus based on three unanimous Buy ratings. The average price target of $9.08 implies more than 120% upside from current levels. Bonello added that current estimates may be conservative, suggesting even greater potential if the company’s financial trajectory clarifies.

Strata Critical Medical, a small-cap healthcare logistics firm, has gained 51% over the past year but remains in penny stock territory. Its core business — air transport and surgical coordination for organ transplants — is niche but critical, with limited competition. The divergence between ARK’s exit and analyst enthusiasm hinges on whether the market sees Strata as a speculative play or a structural bet on transplant logistics.

The average analyst price target is $9.08, implying over 120% upside from the current share price.